PMCPA Case
| Case number | AUTH/2717/5/14 |
| Company | Roche Products Ltd |
| Product | MabThera (rituximab) / MabThera subcutaneous (sc) |
| Material/channel | Journal advertising in the British Journal of Haematology (BJH) |
| Issue/date | May-II edition (19 May) (bound-in card intended for June-I) |
| What went wrong | Two separate double-page ads appeared in one issue (covers + bound-in card), resulting in four pages of advertising for the same product |
| How identified | Voluntary admission (treated as a complaint under Paragraph 5.6 of the Constitution and Procedure) |
| Breach clauses | Clause 6.3 |
| Applicable Code year | 2014 |
| Panel finding | Breach of Clause 6.3 (company responsible for third parties acting on its behalf) |
| Sanction | Undertaking received |
| Complaint received | 23 May 2014 |
| Case completed | 1 July 2014 |
| Appeal | No appeal |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.